Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

FDA Approves New Indication for Wyeth’s TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia

By Pharmaceutical Processing | March 24, 2009

Wyeth Pharmaceuticals, a division of Wyeth, announced today that the FDA approved TYGACIL® (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens. TYGACIL was first approved by the FDA in 2005 for the treatment of complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI) caused by susceptible strains of indicated pathogens in adults. “The approval of this new indication is timely. Antibiotic resistance continues to grow and new antimicrobials are needed,” says Joseph Camardo, M.D., Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals. “The approval of TYGACIL for CABP is an important milestone in Wyeth’s commitment to exploring new treatment options in the anti-infective therapeutic area.” Thomas File, M.D., Chief of Infectious Disease Services for Summa Health System in Akron, Ohio, says, “CABP is a serious and potentially fatal respiratory disease that affects millions of Americans each year. The approval of TYGACIL for CABP means that physicians will have an additional option available to treat patients suffering from the disease.” CABP accounts for an estimated 4.5 million visits to physician offices, emergency departments, and outpatient clinics each year.

Related Articles Read More >

Glass vials moving through the filling station of a Flexicon liquid filling machine
How local regulations are becoming global pharma manufacturing standards 
AI in clinical trials: practical uses and limits
A photo of Fujifilm Biotechnologies' Holly Springs, North Carolina, facility.
Fujifilm Biotechnologies selected for FDA PreCheck Pilot Program
Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE